Skip to main content
. 2020 Nov 6;12:11411–11419. doi: 10.2147/CMAR.S260825

Table 2.

Univariate and Multivariate Analyses of Pretreatment Factors on OS of the patients

Prognostic Variables Univariate Analysis Multivariate Analysis
HR (95% CI) p value HR (95% CI) p value
Gender (female vs male) 0.594 (0.339–1.043) 0.07 0.482 (0.260–0.892) 0.173
Age (≥46 vs <46) 0.214 (0.83–2.302) 0.049 1.306 (0.714–2.389) 0.386
WBC (≥53.8 vs <53.8 x 109/L) 0.900 (0.521–1.556) 0.707 1.642 (0.843–3.198) 0.145
Hb concentration (≥81 vs <81g/dL) 0.775 (0.460–1.304) 0.337 0.675 (0.375–1.216) 0.19
Platelet count (≥78 vs <78 x 1012/L) 0.593 (0.341–1.032) 0.064 0.456 (0.240–0.865) 0.016
Bone marrow blast (≥63% vs <63%) 1.173 (0.705–1.951) 0.54 0.616 (0.323–1.176) 0.142
ELN risk classification 0.910 (0.670–1.234) 0.544 0.736 (0.484–1.120) 0.152
Cytogenetics aberrations classified 0.760 (0.552–1.048) 0.094 0.671 (0.455–0.988) 0.043
NPM1 mutation 1.008 (0.458–2.221) 0.544 0.730 (0.267–1.995) 0.539
FLT3-ITD mutation 1.911 (1.008–3.622) 0.021 1.966 (0.943–5.200) 0.047
TF-PDC (Negative vs Positive) 2.111 (1.268–3.515) 0.004 3.190 (1.748–5.820) 0.002